Abstract
Inflammation has become a research hotspot in solid tumours and has been confirmed as a key factor in tumour development through the interactions of inflammatory mediators with gene expression, cell proliferation, and apoptosis. Pancreatic cancer (PC) is one of the most aggressive and deadliest forms of gastrointestinal cancer. A large case-control study found that aspirin, an anti-inflammatory drug, was associated with a decreased risk of PC. Moreover, aspirin has been shown to have inhibitory effects on PC in both in vitro and in vivo studies. However, the clinical data analysis has not been similarly promising. Results from genetic and pharmacological studies suggest that the anti-tumour effects of aspirin are mediated, at least in part, through the inhibition of COXs. Furtermore, other results suggest that the chemopreventive and therapeutic effects of aspirin are also mediated through COX-independent mechanisms. The COX-dependent and COX-independent mechanisms will be described in this review. In addition, we will discuss future research directions on the risks and benefits of the use of aspirin to treat PC and the potential cellular/molecular.
Keywords: Aspirin, anti-cancer therapy, chemopreventive effect, cellular target, COX2, inflammation, non-steroidal antiinflammatory drugs, pancreatic cancer.
Current Medicinal Chemistry
Title:Aspirin: A Potential Therapeutic Approach in Pancreatic Cancer
Volume: 20 Issue: 33
Author(s): Xin Shen, Liang Han, Zhenhua Ma, Chao Chen, Wanxing Duan, Shuo Yu, Pei Li, Lun Zhang, Wei Li, Qinhong Xu and Qingyong Ma
Affiliation:
Keywords: Aspirin, anti-cancer therapy, chemopreventive effect, cellular target, COX2, inflammation, non-steroidal antiinflammatory drugs, pancreatic cancer.
Abstract: Inflammation has become a research hotspot in solid tumours and has been confirmed as a key factor in tumour development through the interactions of inflammatory mediators with gene expression, cell proliferation, and apoptosis. Pancreatic cancer (PC) is one of the most aggressive and deadliest forms of gastrointestinal cancer. A large case-control study found that aspirin, an anti-inflammatory drug, was associated with a decreased risk of PC. Moreover, aspirin has been shown to have inhibitory effects on PC in both in vitro and in vivo studies. However, the clinical data analysis has not been similarly promising. Results from genetic and pharmacological studies suggest that the anti-tumour effects of aspirin are mediated, at least in part, through the inhibition of COXs. Furtermore, other results suggest that the chemopreventive and therapeutic effects of aspirin are also mediated through COX-independent mechanisms. The COX-dependent and COX-independent mechanisms will be described in this review. In addition, we will discuss future research directions on the risks and benefits of the use of aspirin to treat PC and the potential cellular/molecular.
Export Options
About this article
Cite this article as:
Shen Xin, Han Liang, Ma Zhenhua, Chen Chao, Duan Wanxing, Yu Shuo, Li Pei, Zhang Lun, Li Wei, Xu Qinhong and Ma Qingyong, Aspirin: A Potential Therapeutic Approach in Pancreatic Cancer, Current Medicinal Chemistry 2013; 20 (33) . https://dx.doi.org/10.2174/09298673113209990196
DOI https://dx.doi.org/10.2174/09298673113209990196 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Mechanisms of Resistance to Photodynamic Therapy
Current Medicinal Chemistry Therapeutic Outlook of Pyrazole Analogs: A Mini Review
Mini-Reviews in Medicinal Chemistry Traditional Chinese Medicines (TCMs) for Molecular Targeted Therapies of Tumours
Current Drug Discovery Technologies Inhibitors of the Microsomal Prostaglandin E2 Synthase-1 as Alternative to Non Steroidal Anti-Inflammatory Drugs (NSAIDs) – A Critical Review
Current Medicinal Chemistry Polyphenolic Compounds: Interactions with the Gut and Implications for Human Health
Current Medicinal Chemistry The JNK Signaling Pathway Is a Novel Molecular Target for S-Propargyl- L-Cysteine, a Naturally-Occurring Garlic Derivatives: Link to Its Anticancer Activity in Pancreatic Cancer In Vitro and In Vivo
Current Cancer Drug Targets Biological Denitrification: Screening of Packing Material, Comparison of Denitrification Rate by Pseudomonas aeruginosa and Pseudomonas stutzeri, Application and Design of Bioreactor
Current Environmental Engineering Newly Identified Tumor Antigens as Promising Cancer Vaccine Targets for Malignant Melanoma Treatment
Current Topics in Medicinal Chemistry Peptide Vaccines for Cancer Therapy
Recent Patents on Inflammation & Allergy Drug Discovery Anti-inflammatory Potential of Alkaloids as a Promising Therapeutic Modality
Letters in Drug Design & Discovery Antiangiogenic Gene Therapy in Cancer
Current Genomics Potential Therapeutic Targets of Curcumin, Most Abundant Active Compound of Turmeric Spice: Role in the Management of Various Types of Cancer
Recent Patents on Anti-Cancer Drug Discovery Hepatic Effects of Duloxetine-I: Non-Clinical and Clinical Trial Data
Current Drug Safety Role of Antimicrobial Peptides Expressed by Host Cells Upon Infection by Helicobacter pylori
Protein & Peptide Letters Role of Isoprenoid Compounds on Angiogenic Regulation: Opportunities and Challenges
Current Medicinal Chemistry Near-infrared Light Activatable Multimodal Gold Nanostructures Platform: An Emerging Paradigm for Cancer Therapy
Current Cancer Drug Targets Significance of Prion and Prion-Like Proteins in Cancer Development, Progression and Multi-Drug Resistance
Current Cancer Drug Targets Production of Active MMP7 in E. coli and Its Application for Metalloproteinase Inhibitors Screening
Protein & Peptide Letters Human Defensins: Synthesis and Structural Properties
Current Pharmaceutical Design Neuropeptide Y Induces Cardiomyocyte Hypertrophy <i>via</i> Attenuating miR-29a-3p in Neonatal Rat Cardiomyocytes
Protein & Peptide Letters